2q37 deletion syndrome

2q37 deletion syndrome is a rare genetic disorder characterized by the loss of a fragment of chromosome 2 on the long arm at 2q37. The disorder results from a deletion that results in a variety of manifestations, including intellectual disability, developmental delay, physical developmental abnormalities, and various associated medical conditions. Symptoms may vary from patient to patient, making diagnosis difficult and requiring an individualized approach to treatment. In this context, pathological manifestations may include neurological disorders, organ dysfunction, and characteristic facial features, all of which are due to abnormalities in the genetic code.

History of the disease and interesting historical facts

2q37 deletion syndrome was first described in the scientific literature in the late 1990s, when researchers began actively studying the genetic causes of various congenital anomalies and syndromes. The most important discovery about this pathology was associated with the improvement of molecular genetic technologies, which allow identifying small deletions at the DNA level. Since then, several clinical cases and studies have been published, which contributed to a better understanding of the clinical picture of the syndrome and its potential genetic mechanisms. Interestingly, one of the large registration projects recorded more than 200 cases of this disease, which suggests that it is rare.

Epidemiology

According to various epidemiological studies, the prevalence of 2q37 deletion syndrome is estimated to be approximately 1 in 50,000 to 100,000 live births. This indicates that the disorder is quite rare. However, due to advances in genetic testing, it is possible that the actual prevalence may be higher, as some cases may remain undiagnosed. According to clinical registries, the underlying cases of the syndrome are most often found in preschool and primary school-aged children.

Genetic predisposition to this disease

Deletion in the 2q37 region may affect various genes, resulting in multiple phenotypic manifestations of the syndrome. Among the genes involved are those responsible for the development of the nervous system and the regulation of cell growth. The most well-known are genes such as EBF3, which are involved in neurogenesis and may affect cognitive development. The role of genes associated with atypical development of facial structures is also known. Mutations in these genes may be associated with disorders that manifest under conditions that determine a genetic predisposition to this disease.

Risk factors for the development of this disease

Risk factors for developing 2q37 deletion syndrome include:

• Parental age: increased risk in mothers over 35
• Previous miscarriages or developmental anomalies in previous pregnancies
• Environmental factors: exposure to toxic chemicals during pregnancy
• Family history of genetic disorders: presence of developmental delays and birth defects in the family

These factors may influence the likelihood of developing this genetic abnormality, but most cases are sporadic and occur without an apparent cause.

Diagnosis of this disease

Diagnosis of 2q37 deletion syndrome involves several steps, starting with a clinical examination and observation of symptoms:

• Main symptoms: developmental delay, mental retardation, characteristic facial features, cardiac and nephrological abnormalities
• Laboratory tests: chromosome analysis and molecular genetic testing (eg, FISH or microarray analysis)
• Radiological examinations: ultrasound of organs, X-rays to detect abnormalities in bone structure
• Other types of diagnostics: assessment of the patient's cognitive and physical development
• Differential diagnosis: exclusion of other syndromes with similar clinical manifestations, such as Klippel-Feil, Patau or Edwards syndromes

An accurate diagnosis helps determine a treatment plan and monitor the patient's condition.

Treatment

Treatment of 2q37 deletion syndrome is symptomatic and requires a comprehensive approach:

• General treatment: rehabilitation programs aimed at developing motor and social skills
• Pharmacological treatment: the use of medications to correct associated conditions such as hyperactivity and anxiety
• Surgical treatment: correction of anatomical abnormalities, if any, such as correction of heart defects
• Other types of treatment: speech therapy and psychotherapy to support the child's emotional state

An important aspect is the interdisciplinary approach, involving specialists from different fields to ensure the best results for the patient.

List of medications used to treat this disease

Medications that may be used to treat 2q37 deletion syndrome include:

• Drugs for the correction of psychoemotional state (for example, selective serotonin reuptake inhibitors)
• Anti-fibrotic and anti-inflammatory agents to maintain the health of internal organs
• Dietary supplements to support the immune system

Each treatment should be prescribed by a physician depending on the patient's condition and individual needs.

Disease monitoring

Monitoring the condition of a patient with 2q37 deletion syndrome includes regular follow-up examinations:

• Assessment of growth and development: regular measurement of height and weight, psychomotor development
• Prognosis: depends on the severity of the syndrome, the presence of concomitant diseases and the timeliness of assistance
• Complications: possible problems with the cardiovascular system, respiratory function and psycho-emotional state

Early diagnosis and regular monitoring can help improve the quality of life for patients and their families.

Age-related features of the disease

2q37 deletion syndrome manifests itself differently in different age groups:

• In infancy: delayed motor development and lack of response to stimuli
• In childhood: pronounced problems with learning and adaptation in society
• In adulthood: Most patients retain some cognitive impairment but can successfully integrate into society with appropriate support

Each age period requires a special approach and support from parents and medical specialists.

Questions and Answers

• What is 2q37 deletion syndrome?
  2q37 deletion syndrome is a rare genetic disorder caused by the loss of part of chromosome 2, resulting in developmental delays, intellectual disabilities, and multiple other medical problems.
• How is 2q37 deletion syndrome diagnosed?
  Diagnosis includes clinical examination, chromosomal analysis and molecular genetic testing, as well as differential diagnosis to exclude other syndromes.
• Can 2q37 deletion syndrome be cured?
  There is currently no cure for the syndrome; treatment focuses on symptom management and patient support.
• What are the main symptoms of the syndrome?
  The main symptoms include developmental delay, mental retardation, facial abnormalities, and associated medical conditions such as heart defects.
• What is the prognosis for patients with 2q37 deletion syndrome?
  The prognosis depends on the severity of the symptoms and the results of treatment; many patients can lead an active life with appropriate support and rehabilitation.